Data gathered: November 27
AI Stock Analysis - Halozyme Therapeutics (HALO)
Analysis generated November 16, 2024. Powered by Chat GPT.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) is a biopharmaceutical company focused on developing and commercializing oncology and drug-delivery therapies. Halozyme partners with pharmaceutical and biotechnology companies to apply its proprietary ENHANZE® technology, an enzyme-based drug delivery system, to improve the efficacy and efficiency of injectable drugs and biologics. The company’s innovative approaches and collaborations have positioned it as a key player in the drug delivery market.
Stock Alerts - Halozyme Therapeutics (HALO)
 |
Halozyme Therapeutics | November 26 Employee Rating is up by 3% over the last month. |
|
Halozyme Therapeutics | November 26 Business Outlook among employees is up by 7.7% over the last month. |
|
Halozyme Therapeutics | November 22 Price is up by 5% in the last 24h. |
|
Halozyme Therapeutics | November 19 Price is up by 5.1% in the last 24h. |
Alternative Data for Halozyme Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 11 | Sign up | Sign up | Sign up |
| Sentiment | 96 | Sign up | Sign up | Sign up |
| Webpage traffic | 12,000 | Sign up | Sign up | Sign up |
| Employee Rating | 68 | Sign up | Sign up | Sign up |
| Google Trends | 16 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 7 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 4,673 | Sign up | Sign up | Sign up |
| Twitter Followers | 582 | Sign up | Sign up | Sign up |
| Twitter Mentions | 2,583 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 70 | Sign up | Sign up | Sign up |
| Linkedin Employees | 467 | Sign up | Sign up | Sign up |
About Halozyme Therapeutics
Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally.
| Price | $48.47 |
| Target Price | Sign up |
| Volume | 568,700 |
| Market Cap | $6.08B |
| Year Range | $37.81 - $64.42 |
| Dividend Yield | 0% |
| PE Ratio | 15.82 |
| Analyst Rating | 44% buy |
| Industry | Biotechnology |
In the news
 |
HALO Withdraws Acquisition Bid for EVO, Reaffirms '24 View, Stock UpNovember 24 - Yahoo |
 |
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Receives Consensus Rating of “Moderate Buy” from BrokeragesNovember 23 - ETF Daily News |
|
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Purchased by Quest Partners LLCNovember 23 - ETF Daily News |
|
3,691 Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Purchased by CIBC Asset Management IncNovember 23 - ETF Daily News |
|
Thrivent Financial for Lutherans Decreases Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)November 22 - ETF Daily News |
 |
Halozyme Therapeutics (HALO) Upgraded to Buy: Here's WhyNovember 22 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 290M | 108M | 182M | 137M | 185M | 1.270 |
| Q2 '24 | 231M | 93M | 138M | 93M | 135M | 0.910 |
| Q1 '24 | 191M | 81M | 110M | 77M | 118M | 0.790 |
| Q4 '23 | 225M | 113M | 112M | 85M | 130M | 0.820 |
| Q3 '23 | 212M | 110M | 101M | 82M | 127M | 0.750 |
Insider Transactions View All
| LaBarre Michael J. filed to sell 173,756 shares at $53.3. October 16 '24 |
| LaBarre Michael J. filed to sell 173,756 shares at $54.2. October 16 '24 |
| LaBarre Michael J. filed to sell 173,833 shares at $53.7. October 16 '24 |
| Torley Helen filed to sell 679,148 shares at $53.3. October 9 '24 |
| Torley Helen filed to sell 676,744 shares at $53.9. October 9 '24 |
Similar companies
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Daniel S. Goldman Democrat |
Aug 13, 23 | Sell | $15K - $50K |
| Joshua Gottheimer Democrat |
Jan 13, 23 | Sell | $1K - $15K |
Read more about Halozyme Therapeutics (HALO) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Halozyme Therapeutics?
The Market Cap of Halozyme Therapeutics is $6.08B.
What is Halozyme Therapeutics' PE Ratio?
As of today, Halozyme Therapeutics' PE (Price to Earnings) ratio is 15.82.
What is the current stock price of Halozyme Therapeutics?
Currently, the price of one share of Halozyme Therapeutics stock is $48.47.
How can I analyze the HALO stock price chart for investment decisions?
The HALO stock price chart above provides a comprehensive visual representation of Halozyme Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Halozyme Therapeutics shares. Our platform offers an up-to-date HALO stock price chart, along with technical data analysis and alternative data insights.
Does HALO offer dividends to its shareholders?
As of our latest update, Halozyme Therapeutics (HALO) does not offer dividends to its shareholders. Investors interested in Halozyme Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Halozyme Therapeutics?
Some of the similar stocks of Halozyme Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.